Loading
PregLem
PregLem is a Geneva biotech, part of Gedeon Richter, whose ulipristal acetate (Esmya) for uterine fibroids went through phase 3 trials it led; it is listed among industry sponsors of cancer-tagged trials.
Also called: PregLem SAPregLem S.A.
Overview
PregLem SA, founded in Geneva in 2006 and later acquired by the Hungarian group Gedeon Richter, developed ulipristal acetate (Esmya) for the treatment of uterine fibroids, a benign gynaecological tumour. Its phase 3 programme is registered on ClinicalTrials.gov, where the trials fall under the cancer and neoplasm categories that OnCo's sponsor list draws on.
Connected
2Similar pages
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
- CompanyVion Pharmaceuticals
- CompanyCyclacel Pharmaceuticals
- CompanyJW Pharmaceutical
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
preglem.com · 1
wikidata.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/